Compare ARM & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARM | JNJ |
|---|---|---|
| Founded | 1990 | 1886 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.0B | 542.4B |
| IPO Year | 2023 | 2003 |
| Metric | ARM | JNJ |
|---|---|---|
| Price | $348.88 | $239.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 20 |
| Target Price | $180.75 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 11.7M | 7.4M |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $23.51 | $6.63 |
| Revenue Next Year | $21.05 | $7.43 |
| P/E Ratio | $169.67 | ★ $111.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $100.02 | $151.01 |
| 52 Week High | $452.70 | $251.71 |
| Indicator | ARM | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 59.22 |
| Support Level | $114.24 | $233.83 |
| Resistance Level | $427.99 | $244.80 |
| Average True Range (ATR) | 36.01 | 4.73 |
| MACD | -6.09 | 0.43 |
| Stochastic Oscillator | 32.90 | 77.95 |
Arm Holdings is the IP owner and developer of the Arm architecture, which is used in 99% of the world's smartphone CPU cores. It also has high market share in other battery-powered devices like wearables, tablets, and sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allow them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Both off-the-shelf and architectural customers pay a royalty fee per chip shipped. In 2026, Arm announced the launch of its own CPU products on top of its existing royalty business.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.